Drug
Alks 9072
Alks 9072: highest development phase Phase 1, developed by Alkermes. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 9072, Low dose NCT01493726 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Alks 9072 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.